ClinicalTrials.gg
Not yet recruitingNCT07939022Updated Nov 16, 2026

A Comprehensive Psychometric Validation of EQ Instruments for Early Childhood Health-Related Quality of Life and Caregiver Spillover

An observational study in Asthma (Diagnosis), Diarrhea and Pneumonia, sponsored by RenJi Hospital. Not yet recruiting. Open to participants aged 0 Months to 48 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by RenJi Hospital · Observational

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
450
Ages
0 Months to 48 Months
Sex
All
01

Study summary

This study aims to address critical gaps in the measurement of health-related quality of life (HRQoL) in children under the age of five by conducting a comprehensive psychometric validation of the EQ-TIPS instrument, including both 3-level and 5-level versions. We will conduct a longitudinal study using both quantitative and qualitative methods to assess the feasibility, face validity, known-groups validity, test-retest reliability, and responsiveness of both EQ-TIPS-3L and EQ-TIPS-5L in children aged 0-48 months. For children aged 25-48 months, we will also examine the comparability and potential transition between EQ-TIPS-5L and the proxy version of EQ-5D-Y-5L. In addition, we aim to explore spillover effects on family carers by evaluating the psychometric performance, such as known-groups validity, test-retest reliability, and responsiveness of two newly developed EQ-5D-5L bolt-on items (sleep and fatigue) and the EQ-HWB-9. A total of 450 participants will be recruited from three tertiary hospitals in China across three health condition groups: acute illnesses (n=180), chronic conditions (n=180), and healthy controls (n=90), with an approximately balanced distribution across age groups and disease severity levels. The survey questionnaires will include two parts: 1) Child section: EQ-TIPS-3L, EQ-TIPS-5L, proxy EQ VAS, EQ-5D-Y-5L proxy version 1 (only for children aged 25-48 months), a 5-grade overall health assessment (OHA) proxy version, QQ-10 questionnaire, and children's demographic information; 2) Carer section: carers' EQ-5D-5L with sleep and fatigue bolt-ons, carers' EQ VAS, carers' EQ-HWB-9, and carers' demographic information. Each clinical condition is selected for its high prevalence and clinical relevance in early childhood, as well as its suitability for stratifying health status by severity. Additionally, to assess face validity, carers will complete the QQ-10 questionnaire after completing the EQ-TIPS questionnaire to provide structured feedback on the clarity, relevance, and acceptability of EQ-TIPS. Findings will contribute essential evidence to support the use of EQ-TIPS in early childhood HRQoL assessment and of the EQ-5D-5L bolt-ons and EQ-HWB-9 in evaluating caregiver spillover effects. The study data will be shared with the EuroQol Group to support future development and application of these instruments.

02

Conditions studied

  • Asthma (Diagnosis)
  • Diarrhea
  • Pneumonia
  • Haematological Malignancies

Keywords

  • EQ-TIPS
  • infants
  • Health-Related Quality of Life
  • Psychometric Validation
  • EQ-5D-Y-5L
  • EQ-HWB-S
  • Caregiver Spillover Effects
03

In context

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

This study's planned enrollment of 450 is above the median of 159 across 1,252 observational studies indexed under Asthma.

Browse Asthma studies →

Lead sponsor

RenJi Hospital is the lead sponsor of 551 studies on the registry; 248 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Months to 48 Months
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population will consist of 450 children aged 0-48 months and their primary family carers recruited from three tertiary hospitals in China. Participants will be enrolled into three groups: acute illnesses (pneumonia and diarrhoea, n=180), chronic conditions (haematological malignancies and asthma, n=180), and healthy controls (n=90). Recruitment will aim for balanced representation across age groups (0-24 and 25-48 months) and disease severity levels. Children with illnesses will be recruited from outpatient clinics and inpatient departments, while healthy controls will be recruited during routine physical examinations. Primary family carers will serve as proxy respondents for child health assessments and complete questionnaires assessing their own health and well-being.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -Children aged 0-48 months at enrolment.
  • Children diagnosed with pneumonia, acute diarrhoea, haematological , or asthma; or healthy children without known medical conditions attending routine physical examinations.
  • Availability of a primary family carer (parent, grandparent, or legal guardian) who has primarily cared for the child during the preceding month, including supervision of daily activities and health-related care.
  • The primary family carer accompanies the child during the outpatient visit, inpatient admission, or routine physical examination.
  • The primary family carer is able to understand the study information and provides written .

Exclusion criteria

Exclusion Criteria:

  • Children older than 48 months at enrolment.
  • Primary family carers unable to read or understand Chinese.
  • Primary family carers with cognitive impairments that prevent questionnaire completion.
  • Absence of written .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
450 participants (estimated)
Patient registry
No

Groups and cohorts

  • Acute Illness Group

    Children aged 0-48 months diagnosed with acute illnesses, including pneumonia (n=90) and acute diarrhoea (n=90). Participants will be recruited across different disease severity levels. Their primary family carers will complete proxy-reported health-related quality of life assessments at baseline and follow-up, while also reporting their own health and well-being.

    Other: Health-Related Quality of Life Assessment Using EuroQol Instruments

  • Chronic Illness Group

    Children aged 0-48 months diagnosed with chronic conditions, including haematological malignancies (n=90) and asthma (n=90). Participants will represent different levels of disease severity. Their primary family carers will complete proxy-reported health-related quality of life assessments at baseline and follow-up, alongside assessments of their own health and caregiver spillover effects

    Other: Health-Related Quality of Life Assessment Using EuroQol Instruments

  • Healthy Control Group

    Group/Cohort Description: Age-matched healthy children aged 0-48 months (n=90), with no known medical conditions at the time of assessment, recruited during routine physical examinations. Their primary family carers will complete the same proxy-reported child health and caregiver health-related quality of life assessments as those in the illness groups.

    Other: Health-Related Quality of Life Assessment Using EuroQol Instruments

Interventions

  • OtherHealth-Related Quality of Life Assessment Using EuroQol Instruments

    This study involves longitudinal health-related quality of life assessments of children aged 0-48 months and their primary family carers. Carers will complete the EQ-TIPS-3L and EQ-TIPS-5L as proxy respondents for their children. For children aged 25-48 months, the proxy EQ-5D-Y-5L will also be administered. Carers will additionally complete the EQ-5D-5L with sleep and fatigue bolt-on items and the EQ-HWB-9 to assess caregiver spillover effects. Assessments will be conducted at baseline and follow-up using tablet-based questionnaires. No therapeutic interventions will be assigned as part of the study.

06

What researchers measure

Primary outcomes

  1. Known-Groups Validity of EQ-TIPS-3L and EQ-TIPS-5L

    Known-groups validity will be evaluated by comparing EQ-TIPS-3L and EQ-TIPS-5L level sum scores (LSS) across predefined clinical severity categories and overall health assessment (OHA) categories. Cohen's d and relative efficiency based on ANOVA F-statistics will be calculated to assess the instruments' discriminatory ability.

    Time frame: Baseline

  2. Test-Retest Reliability of EQ-TIPS-3L and EQ-TIPS-5L

    Test-retest reliability will be evaluated among children whose health status remains stable between baseline and follow-up, as determined by unchanged clinical severity and overall health assessment (OHA). Intraclass correlation coefficients (ICCs) will be calculated for EQ-TIPS level sum scores (LSS), and Gwet's agreement coefficients will be calculated for individual dimensions.

    Time frame: Baseline and follow-up (at least 3 days after baseline; timing varies by clinical condition)

  3. Responsiveness of EQ-TIPS-3L and EQ-TIPS-5L to Changes in Child Health

    Responsiveness will be evaluated by changes in EQ-TIPS-3L and EQ-TIPS-5L scores between baseline and follow-up among children classified as improved, stable, or deteriorated based on clinical indicators and overall health assessment (OHA). Standardised effect size (SES), standardised response mean (SRM), and Paretian Classification of Health Change (PCHC) will be calculated.

    Time frame: Baseline and follow-up (at least 3 days after baseline; timing varies by clinical condition)

Secondary outcomes

  1. Face Validity and Acceptability of EQ-TIPS-3L and EQ-TIPS-5L

    Face validity and acceptability will be assessed using the QQ-10 questionnaire completed by family carers. Quantitative responses will evaluate perceived value, clarity, relevance, and acceptability. Open-ended responses will undergo thematic content analysis to identify concerns regarding comprehensiveness, redundancy, and questionnaire burden.

    Time frame: Baseline

  2. Comparative Psychometric Performance of EQ-TIPS-3L and EQ-TIPS-5L

    EQ-TIPS-3L and EQ-TIPS-5L will be compared in terms of missing responses, response distributions, ceiling effects, known-groups validity, test-retest reliability, and responsiveness to health change. Ceiling effects will be assessed using the proportion of children reporting no problems across all dimensions.

    Time frame: Baseline and follow-up (at least 3 days after baseline; timing varies by clinical condition)

  3. Psychometric Performance of EQ-5D-5L With Sleep and Fatigue Bolt-Ons and EQ-HWB-9 in Family Carers

    Caregiver outcomes will be evaluated using EQ-5D-5L with sleep and fatigue bolt-on items and EQ-HWB-9. Analyses will assess response distributions, ceiling effects, known-groups validity, test-retest reliability, and responsiveness to changes in child health. Regression analyses will explore associations with child disease severity, caregiving time, and caregiver burden.

    Time frame: Baseline and follow-up (at least 3 days after baseline; timing varies by clinical condition)

07

Study locations

No study locations are listed for this record.

08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2027, 12 months later.

Of 365 non-industry observational studies under Asthma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 97. This study's planned 12 months is below that.

Counting every sponsor, half of 455 studies reached it within 36 months; a quarter within 18 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 16, 2026
StartEst.
Dec 10, 2026
Primary completionEst.
Dec 10, 2027
CompletionEst.
Dec 9, 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07939022
Lead sponsor
RenJi Hospital
Collaborators
The EuroQol Research Foundation, The Children's Hospital of Zhejiang University School of Medicine, The Affiliated Hospital Of Guizhou Medical University
Responsible party
Wenjing Zhou (doctor, RenJi Hospital) — Principal investigator
First posted
Nov 16, 2026
Start date
Dec 10, 2026 (estimated)
Primary completion
Dec 10, 2027 (estimated)
Completion
Dec 9, 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Wenjing Zhou, PhD
Contact
zhoujing2188@163.com
86-13817114768

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion